Outcomes of patients with pelvic leiomyosarcoma treated by surgery and relevant auxiliary diagnosis

作     者：Qian Sun Xin Yang Zhen Zeng Xiao Wei Ke-Zhen Li Xiao-Yan Xu 

作者机构：Department of Obstetrics and GynaecologyTongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030Hubei ProvinceChina 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2020年第8卷第10期

页      面：1887-1896页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by National Natural Science Foundation of China,No81501530 Scientific Research Projects of Hubei Health Commission,No. WJ2019M130 Scientific Research Fund of Tongji Hospital,No. 2018B02 

主　　题：Uterine leiomyosarcoma Non-uterine leiomyosarcoma Serum biomarker Prognosis Ultrasonography 

摘      要：BACKGROUND Leiomyosarcoma is a subtype of soft tissue sarcoma with adverse *** accounts for nearly 70%of all uterine sarcomas and is responsible for a considerable proportion of deaths because of uterine *** characteristics and relevant diagnosis of pelvic leiomyosarcoma should be further *** To identify the outcome and relevant perioperative evaluation of patients with pelvic *** The Kaplan-Meier method was used to determine progression-free survival and overall survival *** predictive of outcomes were identified using univariate and multivariate Cox proportional hazards *** Fifty-one patients with pelvic leiomyosarcoma were enrolled and divided into two groups including uterine leiomyosarcoma and non-uterine ***,28.6%and 45.5%of uterine leiomyosarcoma and non-uterine leiomyosarcoma patients,respectively,had elevated carbohydrate antigen 125 levels,whereas 45.7%and 68.8%,respectively,underwent *** 68.8%of uterine leiomyosarcoma patients were initially diagnosed with hysteromyoma,72.7%of non-uterine leiomyosarcoma patients had pelvic and abdominal ***,93.3%of the recurrent lesions were detected using *** with International Federation of Gynaecology and Obstetrics(FIGO)stages III–IV disease had poorer progression-free survival values than those with FIGO stages I–II(P=0.027)*** stage was significantly associated with poor progression-free survival in the univariate(hazard ratio=2.64,P=0.03)and multivariate(hazard ratio=2.49,P=0.048)*** Serum tumour biomarkers cannot be used for pelvic leiomyosarcoma *** stage is critical to predict the outcome of uterine *** is more reliable for postoperative follow-up than preoperative diagnosis.